IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant.
Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study / Ruggiero, Angelo; Fabbrocini, Gabriella; Cinelli, Eleonora; Megna, Matteo. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 35:1(2022). [10.1111/dth.15214]
Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study
Ruggiero, Angelo;Fabbrocini, Gabriella;Cinelli, Eleonora;Megna, Matteo
2022
Abstract
IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
